Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

The president is planning Monday to revive a plan from his first term, which would peg the prices the United States pays for ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their ...

Over the next eight years, Eli Lilly and Company and Purdue University will continue their partnership. According to an announcement on Friday morning, Lilly is expected to ...

Eli Lilly announced a strategic executive shuffle aimed at boosting its U.S. and global operations, especially in ...

Eli Lilly (NYSE:LLY) said Thursday that Ilya Yuffa, executive vice president and president, Lilly International, will become ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Eli Lilly and Co. on Thursday announced three executive leadership transitions that the Indianapolis drugmaker said better ...